Reference : Prevention of Postmenopausal Bone Loss by Tiludronate
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/125038
Prevention of Postmenopausal Bone Loss by Tiludronate
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Lecart, M. P. [> > > >]
Deroisy, Rita mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Sarlet, Nathalie [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Denis, D. [> > > >]
Ethgen, Dominique [Université de Liège - ULg > > Epidémiologie et santé publique >]
Collette, Julien mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
Franchimont, P. [> > > >]
1989
Lancet
2
8678-8679, Dec 23-30
1469-71
Yes (verified by ORBi)
International
0140-6736
[en] 76 healthy women, who had been menopausal for less than 96 months and who had never received any form of treatment to prevent bone loss, were entered into a randomised double-blind study. For the first 6 months, half the patients received tiludronate 100 mg daily, while the others received placebo. During the second 6 months, all patients received placebo. Bone mineral density of the lumbar spine decreased significantly by 2.1% (SE 0.8%) in the placebo group and did not significantly change in the tiludronate group (+1.33 [0.8]%). The difference in response between the groups was significant, as were the differences between values for corrected urinary hydroxyproline and calcium. Treatment with tiludronate was not followed by increased secretion of parathyroid hormone. A 6 month course of oral tiludronate may counteract postmenopausal bone loss for at least a year by decreasing bone resorption.
http://hdl.handle.net/2268/125038

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Prevention of Postmenopausal Bone Loss by Tiludronate.pdfPublisher postprint1.38 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.